The diabetes device maker exceeded second-quarter revenue guidance but reduced its full-year U.S. Omnipod sales growth forecast as it continues scaling in the type 2 diabetes market.
Key Investor Takeaways
- Insulet (NASDAQ:PODD) reported second-quarter revenue growth of 23.5% to $801.7 million, exceeding its guidance range.
- Omnipod revenue increased 24.6%, led by 35.5% international growth, while U.S. Omnipod revenue rose 20.1%.
- The company lowered its full-year U.S. Omnipod growth outlook to 17%-19% from 20%-22%, reducing total revenue guidance to 20%-22%.
- Adjusted operating margin improved by more than 140 basis points, while adjusted EPS increased 41.5% year over year.
- Insulet continued expanding the Omnipod platform through new international launches, product enhancements, and clinical data supporting future automated insulin delivery technologies.
Why PODD Stock Is in Focus
Insulet (NASDAQ:PODD) reported second-quarter 2026 revenue of $801.7 million, up 23.5% from a year earlier and above the high end of its constant-currency guidance. Total Omnipod revenue reached $795.9 million, with U.S. sales climbing 20.1% to $544.1 million and international revenue increasing 35.5% to $251.8 million.
Profitability also strengthened despite continued investment in growth. Net income increased to $95.0 million, or $1.37 per diluted share, compared with $22.5 million, or $0.32 per diluted share, a year ago. Adjusted net income rose 37.4% to $115.0 million, while adjusted earnings per diluted share increased 41.5% to $1.66.
Operationally, the company expanded Omnipod 5 into Spain, making it available in its 20th market, introduced a next-generation automated insulin delivery algorithm with broader sensor compatibility, and presented new clinical data supporting both Omnipod 6 and its fully closed-loop technology for people with type 2 diabetes.
Despite the strong quarterly performance, management updated its 2026 guidance. Full-year U.S. Omnipod revenue growth is now expected at 17%-19%, down from the previous 20%-22% outlook. Total company revenue growth guidance was also lowered to 20%-22% from 21%-23%, although the company maintained expectations for approximately 100 basis points of adjusted operating margin expansion and raised its adjusted EPS growth outlook to more than 30%.
Why This Matters for Investors
The key takeaway for investors is the contrast between another strong operating quarter and a more cautious revenue outlook.
The second-quarter results demonstrate continued demand for the Omnipod platform, particularly outside the United States, where international growth continues to outpace the domestic business. Improved adjusted margins and significantly higher earnings also suggest the company is scaling profitably.
However, the reduction in U.S. Omnipod guidance indicates that commercialization in the type 2 diabetes market may be progressing more gradually than previously anticipated. While management said its long-term confidence remains unchanged, the revised outlook may shift investor attention toward execution in this expanding patient population rather than headline revenue growth alone.
The maintained margin guidance and higher adjusted EPS outlook also suggest Insulet expects operational efficiencies to partially offset the slower expected U.S. sales trajectory.
What to Watch Next
Investors will likely focus on:
- Execution against the revised U.S. Omnipod growth outlook.
- Adoption of Omnipod 5 in newly launched international markets.
- Progress of Omnipod 6 and the company’s fully closed-loop insulin delivery platform.
- Evidence that expansion into the type 2 diabetes market can support longer-term growth while maintaining profitability.
Insulet Corporation stock price
